Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Gamma Delta T Cell Cancer Therapy Opportunity & Clinical Trials Insight 2026

Published by KuicK Research Product code 1001956
Published Content info 180 Pages
Delivery time: 1-2 business days
Price
Back to Top
Gamma Delta T Cell Cancer Therapy Opportunity & Clinical Trials Insight 2026
Published: April 23, 2021 Content info: 180 Pages
Description

“ Gamma Delta T Cell Cancer Therapy Opportunity & Clinical Trials Insight 2026 ” Report Highlights:

  • Commercialization Market Potential After Market Launch: > USD 4 Billion
  • Insight on Key Drugs In Research & Development
  • Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight
  • Gamma Delta T Cell Cancer Therapy In Clinical Trials: > 15 Therapies
  • Gamma Delta T Cell Cancer Therapy Market Opportunity By Cancer Type
  • Adopted Approaches for Gamma Delta T Cell Therapy

Over the past few years, the idea of immunotherapy of ability to manipulate immune cells in targeting tumor cells is gaining momentum in field of cancer therapeutics. Since then scientists have developed a wide range of potential candidates which has shown encouraging results in the management of cancer. The recent clinical success of chimeric antigen receptor in the management of hematological malignancies has clearly led to the explosion in the field of adoptive cell therapy for cancer. Researchers are currently putting efforts for the translation of this exciting technology in solid tumors and the development of allogeneic off the shelf therapies.

With the progress in biotechnology researchers were able to identify gamma delta T cells which have potential role in cancer immunosurveillance and have the potential to overcome the challenges in adoptive cell therapy. The cells have both innate and adaptive like properties, thus bridging between the adaptive and innate immunity. Furthermore, these subsets of cells produce different cytokines, chemokine and growth factors which help in generating immune response against the tumor cells.

Since their identification, gamma delta T cells are attractive candidates for the adoptive T cell therapy due to their unique biology and favorable characteristics in the management of cancer. The unique ability of targeting cells in major histocompatibility complex independent manner and recognizing a broader range of antigens has gained a lot of interest by the researchers. As of now, there are no approved gamma delta T therapies but a pool is present in clinical trials. Majority of the candidates belongs to early phase clinical trial which will require about 5-7 years to enter the market.

The encouraging response of the gamma delta T cell therapy in the management of cancer has surged the researchers for the exploiting the role of gamma delta T cells in other diseases also. A number of preclinical studies have been initiated by researchers to identify their role in diabetes, infectious and autoimmune diseases. As per report, it is expected that global gamma T cell therapy will witness huge growth rate in coming years and the market will be flourished with various potential candidates in management of wide range of diseases.

Despite several restraining factors in the growth of market including low physical frequency, high cost of development and stringent regulatory guidelines the overall market will follow a trajectory path. This is mainly due to the rising partnerships and collaborations among the pharmaceutical companies which increases the investment to carry out research and development activities. The major key players operating in the market are Acopedia, Takeda Pharma, TC Biopharma and Adapate Therapeutics which have robust clinical pipeline of gamma delta T cells candidates.

In coming years, the subsequent rise in the prevalence of cancer and the rates at which conventional therapies are failing will possess unmet need for the development of novel therapies which will drive the gamma delta T cell therapy market. Moreover, the exploitation of the therapy in management of other diseases will also propel the growth of marker. In addition to this, it is analyzed that North America will hold the top position in the global market due to rising geriatric population and increase government initiatives to promote novel therapies. In the forecast period, Europe and Asia-Pacific will also emerge as a potential market due to increase in awareness among the population of the region.

Table of Contents

Table of Contents

1. Introduction to Gamma Delta T Cell Therapy

  • 1.1 Emerging Role of T Cell Based Immunotherapies
  • 1.2 Overview to Gamma Delta T Cell Therapy

2. Gamma Delta T Cell Therapy Vs. Conventional Therapies

  • 2.1 Gamma Delta T Cell Therapy Vs. CAR T Cell Therapy
  • 2.2 Gamma Delta T Cell Therapy Vs. Tumor Infiltrating Lymphocyte Therapy
  • 2.3 Gamma Delta T Cell Therapy Vs. Immune Checkpoint Inhibitors
  • 2.4 Gamma Delta T Cell Therapy Vs. Monoclonal Antibodies
  • 2.5 Gamma Delta T Cell Therapy Vs. Others

3. Role of Gamma Delta T Cells in Cancer

  • 3.1 Gamma Delta T Cells in Cancer Progression
  • 3.2 Anti Tumor Activity of Gamma Delta T Cells

4. Adopted Approaches for Gamma Delta T Cell Therapy

  • 4.1 Gamma Delta T Cell as Bispecific Antibodies
  • 4.2 CAR Gamma Delta T Cells

5. Gamma Delta T Cell Therapy: Key Drugs In Research & Development

  • 5.1 ADI-001
  • 5.2 LAVA-051
  • 5.3 INB-200
  • 5.4 TCB002
  • 5.5 INB-100
  • 5.6 ACE1831
  • 5.7 GDX012

6. Global Gamma Delta T Cell Cancer Therapy Clinical Pipeline Overview

  • 6.1 By Country
  • 6.2 By Company
  • 6.3 By Indication
  • 6.4 By Phase

7. Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight

  • 7.1 Research
  • 7.2 Preclinical
  • 7.3 Phase-I
  • 7.4 Phase-II/III

8. Gamma Delta T Cell Therapy in Leukemia

  • 8.1 Role of Gamma Delta T Cells in Leukemia
  • 8.2 Ongoing Clinical Research in Acute Leukemia
  • 8.3 Clinical Trials in Chronic Lymphocytic Leukemia
  • 8.4 Future Market Opportunity of Gamma Delta T Cells in Leukemia

9. Gamma Delta T Cell Therapy in Lung Cancer

  • 9.1 Overview
  • 9.2 Ongoing Research & Development
  • 9.3 Future Market Opportunity of Gamma Delta T Cell Therapy in Lung Cancer

10. Gamma Delta T Cells in Breast Cancer

  • 10.1 Overview
  • 10.2 Ongoing Research & Development in Breast Cancer
  • 10.3 Future Market Opportunity of Gamma Delta T Cell Therapy in Breast Cancer

11. Gamma Delta T Cells in Colorectal Cancer

  • 11.1 Function of Gamma Delta T Cells in Colorectal Cancer
  • 11.2 Ongoing Clinical Trials in Colorectal Cancer
  • 11.3 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer

12. Gamma Delta T Cells in Pancreatic Cancer

  • 12.1 Overview
  • 12.2 Ongoing Research & Development in Pancreatic Cancer
  • 12.3 Future Market Potential of Gamma Delta Therapy in Pancreatic Cancer

13. Current Clinical Research in Other Cancers

  • 13.1 Ongoing Clinical Trials in Neuroblastoma
  • 13.2 Ongoing Clinical Trials in Glioblastoma
  • 13.3 Ongoing Research & Development in Head & Neck Cancer

14. Gamma Delta T Cell Therapy Market Overview

  • 14.1 Current Market Scenario
  • 14.2 Market Potential of Gamma Delta T Cell Therapy Market

15. Gamma Delta T Cell Therapy Market Dynamics

  • 15.1 Gamma Delta T Cell Therapy Market: Favorable Parameters
  • 15.2 Gamma Delta T Cell Therapy Market: Challenges

16. Gamma Delta T Cell Therapy Future Prospects

17. Competitive Landscape

  • 17.1 Acepodia
  • 17.2 Adaptate Therapeutics
  • 17.3 Adicet
  • 17.4 Cytomed Therapeutics
  • 17.5 Gadeta
  • 17.6 GammaDelta Therapeutics
  • 17.7 IN8bio
  • 17.8 Kiromic Biopharma
  • 17.9 Lava Therapeutics
  • 17.10 Takeda Pharmaceuticals
  • 17.11 TC Biopharm

List of Figures

  • Figure 1-1: History of T cell Based Immunotherapy
  • Figure 1-2: Gamma Delta T cell Therapy
  • Figure 1-3: Stimulants of Gamma Delta T Cells
  • Figure 2-1: Limitation of CAR T Cell Therapy
  • Figure 2-2: Limitations of TIL
  • Figure 2-3: Limitations of Monoclonal Antibodies
  • Figure 2-4: Drawback of Chemotherapeutic Drugs
  • Figure 3-1: Pro-Tumor Role of Gamma Delta T Cells
  • Figure 3-2: Antigen Presentation Functions of Gamma Delta T-Cells
  • Figure 3-3: Anti-Tumor Activity of Gamma Delta T-Cells
  • Figure 4-1: Gamma Delta T Cell Bispecific Antibodies - Mechanism of Action
  • Figure 4-2: Functional Advantages of γδ T Cells for CAR T Cancer Therapy
  • Figure 4-3: CAR γδ T Cells - Mechanism of Action
  • Figure 5-1: ADI-001 - Initiation & Completion Year of Phase-I Clinical Trial
  • Figure 5-2: DRI Cell Therapy - Initiation & Completion Year of Phase-I Clinical Trial
  • Figure 5-3: Adoptive Cell Therapy - Initiation & Completion Year of Phase-I Clinical Trial
  • Figure 6-1: Global - Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Country, 2021 till 2026
  • Figure 6-2: Global - Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Company, 2021 till 2026
  • Figure 6-3: Global - Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Indication, 2021 till 2026
  • Figure 6-4: Global Gamma Delta T Cell Cancer Therapy in Clinical Pipeline by Phase, 2021 till 2026
  • Figure 8-1: Global - Leukemia Incidences & Mortality (Million), 2020 & 2040
  • Figure 8-2: Benefits of Gamma Delta T Cells in Leukemia
  • Figure 8-3: Mechanism of Action of Vγ9/CD123 Bispecific Antibody
  • Figure 8-4: Global - Estimated Leukemia Cancer Cases, 2020-2026
  • Figure 8-5: US - Estimated Leukemia Cancer Cases, 2020-2026
  • Figure 8-6: Europe - Estimated Leukemia Cancer Cases, 2020-2026
  • Figure 8-7: China - Estimated Leukemia Cancer Cases, 2020-2026
  • Figure 8-8: Japan - Estimated Leukemia Cancer Cases, 2020-2026
  • Figure 9-1: Global - Lung Cancer Incidences & Mortality (Million), 2020 & 2040
  • Figure 9-2: Role of Gamma Delta T Cells in Lung Cancer
  • Figure 9-3: Global - Estimated Lung Cancer Cases, 2020-2026
  • Figure 9-4: US - Estimated Lung Cancer Cases, 2020-2026
  • Figure 9-5: Europe - Estimated Lung Cancer Cases, 2020-2026
  • Figure 9-6: China - Estimated Lung Cancer Cases, 2020-2026
  • Figure 9-7: Japan - Estimated Lung Cancer Cases, 2020-2026
  • Figure 10-1: Global - Breast Cancer Incidences (Million), 2020 & 2040
  • Figure 10-2: Global - Breast Cancer Mortality (Million), 2020 & 2040
  • Figure 10-3: Global - Estimated Breast Cancer Cases, 2020-2026
  • Figure 10-4: US - Estimated Breast Cancer Cases, 2020-2026
  • Figure 10-5: Europe - Estimated Breast Cancer Cases, 2020-2026
  • Figure 10-6: China - Estimated Breast Cancer Cases, 2020-2026
  • Figure 10-7: Japan - Estimated Breast Cancer Cases, 2020-2026
  • Figure 11-1: Role of Gamma Delta T Cells in Colorectal Cancer
  • Figure 11-2: Mechanism Underlying B7-H3 Regulating γδ T Cells Killing Colon Cancer Cells
  • Figure 11-3: Global - Estimated Colorectal Cancer Cases, 2020-2026
  • Figure 11-4: US - Estimated Colorectal Cancer Cases, 2020-2026
  • Figure 11-5: Europe - Estimated Colorectal Cancer Cases, 2020-2026
  • Figure 11-6: China - Estimated Colorectal Cancer Cases, 2020-2026
  • Figure 11-7: Japan - Estimated Colorectal Cancer Cases, 2020-2026
  • Figure 12-1: Global - Pancreatic Cancer Incidences, 2020 & 2040
  • Figure 12-2: Global - Pancreatic Cancer Mortality, 2020 & 2040
  • Figure 12-3: Role of Gamma Delta T Cells in Pancreatic Cancer Progression
  • Figure 12-4: Global - Estimated Pancreatic Cancer Cases, 2020-2026
  • Figure 12-5: US - Estimated Pancreatic Cancer Cases, 2020-2026
  • Figure 12-6: Europe - Estimated Pancreatic Cancer Cases, 2020-2026
  • Figure 12-7: China - Estimated Pancreatic Cancer Cases, 2020-2026
  • Figure 12-8: Japan - Estimated Pancreatic Cancer Cases, 2020-2026
  • Figure 14-1: Global - Cell Therapy Market (US$ Billion), 2020 - 2026
  • Figure 14-2: Global - Gamma Delta T Cell Therapy Market Opportunity by 1% of Total Cell Therapy Market (US$ Billion), 2021-2026
  • Figure 14-3: Global - Gamma Delta T Cell Therapy Market Opportunity by 2% of Total Cell Therapy Market (US$ Billion), 2021-2026
  • Figure 14-4: Global - Gamma Delta T Cell Therapy Market Opportunity by 3% of Total Cell Therapy Market (US$ Billion), 2021-2026
  • Figure 14-5: Global - Gamma Delta T Cell Therapy Market Opportunity by 4% of Total Cell Therapy Market (US$ Billion), 2021-2026
  • Figure 14-6: Global - Gamma Delta T Cell Therapy Market Opportunity by 5% of Total Cell Therapy Market (US$ Billion), 2021-2026
  • Figure 14-7: Global - Gamma Delta T Cell Therapy Market Opportunity by 6% of Total Cell Therapy Market (US$ Billion), 2021-2026
  • Figure 14-8: Global - Gamma Delta T Cell Therapy Market Opportunity by 7% of Total Cell Therapy Market (US$ Billion), 2021-2026
  • Figure 14-9: Global - Gamma Delta T Cell Therapy Market Opportunity by 8% of Total Cell Therapy Market (US$ Billion), 2021-2026
  • Figure 14-10: Global - Gamma Delta T Cell Therapy Market Opportunity by 9% of Total Cell Therapy Market (US$ Billion), 2021-2026
  • Figure 14-11: Global - Gamma Delta T Cell Therapy Market Opportunity by 10% of Total Cell Therapy Market (US$ Billion), 2021-2026
  • Figure 15-1: Global - Cancer Incidences & Mortality Rates (Billion), 2020 & 2040
  • Figure 15-2: Gamma Delta T Cells Favorable Market Parameters
  • Figure 15-3: Stages of Drug Development

List of Tables

  • Table 6-1: Global - Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2021-2026
  • Table 6-2: US - Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2021-2026
  • Table 6-3: Europe - Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2021-2026
  • Table 6-4: China - Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2021-2026
  • Table 6-5: Japan - Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2021-2026
  • Table 7-1: Global - Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2021-2026
  • Table 7-2: US - Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2021-2026
  • Table 7-3: Europe - Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2021-2026
  • Table 7-4: China - Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2021-2026
  • Table 7-5: Japan - Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2021-2026
  • Table 8-1: Global - Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2021-2026
  • Table 8-2: US - Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2021-2026
  • Table 8-3: Europe - Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2021-2026
  • Table 8-4: China - Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2021-2026
  • Table 8-5: Japan - Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2021-2026
  • Table 9-1: Global - Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2021-2026
  • Table 9-2: US - Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2021-2026
  • Table 9-3: Europe - Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2021-2026
  • Table 9-4: China - Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2021-2026
  • Table 9-5: Japan - Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2021-2026
  • Table 10-1: Global - Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2021-2026
  • Table 10-2: US - Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2021-2026
  • Table 10-3: Europe - Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2021-2026
  • Table 10-4: China - Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2021-2026
  • Table 10-5: Japan - Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2021-2026
Back to Top